MedMira Inc represents values of innovation, integrity, and commitment to global health. The company's corporate philosophy revolves around developing and delivering innovative, rapid diagnostic solutions that improve healthcare outcomes worldwide. MedMira Inc's dedication to scientific excellence, stringent quality control, and customer satisfaction has positioned them as a trusted leader in the diagnostic industry. With a focus on precision and accuracy, MedMira Inc strives to provide diagnostic tools and technologies that surpass industry standards, ultimately enhancing patient care and contributing to better healthcare practices globally.

MedMira Inc is primarily present in multiple countries and regions worldwide. The company has a global presence, with its products and services being recognized in North America, Europe, Asia, and Africa. MedMira Inc has successfully established a strong foothold in the United States and Canada, where it continues to expand its market share. Additionally, the company has made significant strides in penetrating international markets, including Europe and Asia. With its commitment to delivering innovative healthcare solutions, MedMira Inc aims to provide its products to healthcare professionals and customers globally.

MedMira Inc. has achieved several significant milestones in its history. Firstly, the company developed and commercialized its rapid HIV test, the Reveal G4, which offers quick and accurate results in just three minutes. This breakthrough in technology has helped in detecting HIV infections and preventing their spread. Additionally, MedMira Inc. received regulatory approvals from the World Health Organization (WHO), the U.S. Food and Drug Administration (FDA), and the European Commission (CE Mark) for its innovative product. These milestones have positioned MedMira Inc. as a leader in the field of rapid diagnostics and underscore its commitment to improving global healthcare.

MedMira Inc is a Canadian biotech company specializing in the development and commercialization of rapid diagnostic testing solutions. Founded in 1993, MedMira has gained global recognition for its innovative technologies in infectious disease detection, particularly with regards to HIV and hepatitis C. With a commitment to advancing healthcare accessibility, MedMira has developed a range of rapid testing products that deliver accurate results in a matter of minutes. These tests have found applications in both clinical and non-clinical settings, including hospitals, clinics, blood banks, and research laboratories. MedMira Inc continues to be at the forefront of diagnostic testing solutions, driving advancements in the field of healthcare.

The main competitors of MedMira Inc in the market include companies like Abbott Laboratories, OraSure Technologies, and Chembio Diagnostics.

MedMira Inc is primarily active in the medical diagnostics and biotechnology industries.

MedMira Inc, a leading medical technology company, operates on a business model focused on the development and commercialization of rapid diagnostic solutions. Through extensive research and innovation, MedMira creates advanced tests for infectious diseases, including HIV, hepatitis, and other sexually transmitted infections. These tests are designed to provide accurate and reliable results in a shorter timeframe, enabling healthcare professionals to make informed decisions swiftly. MedMira Inc collaborates with healthcare providers, governments, and distributors worldwide to ensure the widespread availability and accessibility of their diagnostic solutions, ultimately improving patient outcomes and contributing to global health initiatives.

KGV untuk MedMira saat ini tidak dapat dihitung.

KUV untuk MedMira saat ini tidak dapat dihitung.

Skor Kualitas AlleAktien untuk MedMira adalah 5/10.

Pendapatan untuk MedMira saat ini tidak dapat dihitung.

Laba saat ini tidak bisa dihitung untuk MedMira.

MedMira Inc is an internationally active biotechnology company from Canada, specializing in the development, manufacture, and marketing of diagnostic rapid tests for infectious diseases. The company's business model is based on the production and sale of various products used in different areas of healthcare. The broad product portfolio of MedMira includes rapid tests for professional use in clinical laboratories as well as for home use. The company's various divisions focus on the production of diagnostic tests for HIV, hepatitis B and C, syphilis, and other infectious diseases. MedMira produces both individual test kits for direct use by medical personnel and complex systems for use in clinical facilities. The company's focus is on reducing the cost of infection testing without compromising on quality and reliability. An important part of MedMira's business model is research and development of new products. The constant work on new testing methods and technologies allows the company to constantly stay up to date with its products and stand out from the competition. In addition to selling rapid tests, MedMira also offers training and consultations for medical personnel. The goal is to improve understanding of infectious diseases and the importance of early detection tests. Through close collaboration with international development and distribution partners, MedMira has access to various markets and can offer its products worldwide. The company strongly focuses on the needs of end users and providing customized solutions. Overall, MedMira's successful business model is based on a combination of high-quality production capacity, efficient distribution and marketing, and continuous research and development. The company stands for high ethical responsibility and aims to contribute to the improvement of global health.

MedMira membayarkan dividen sebesar 0 CAD yang dibagi melalui pembayaran dalam setahun.

Dividen untuk MedMira saat ini tidak dapat dihitung atau perusahaan tidak membagikan dividen.

ISIN dari MedMira adalah CA58501R1029.

WKN dari MedMira adalah 932414.

Ticker dari MedMira adalah MIR.V.

Dalam 12 bulan terakhir, MedMira membayar dividen sebesar . Ini setara dengan yield dividen sekitar . Untuk 12 bulan mendatang, MedMira diperkirakan akan membayar dividen sebesar 0 CAD.

Imbal hasil dividen dari MedMira saat ini adalah .

MedMira membayar dividen setiap kuartal. Dividen ini dibayarkan pada bulan .

MedMira membayar dividen setiap tahun dalam 0 tahun terakhir.

Untuk 12 bulan ke depan, diperkirakan akan ada dividen sebesar 0 CAD. Ini setara dengan yield dividen sebesar 0 %.

MedMira dikelompokkan dalam sektor 'Kesehatan'.

Untuk menerima dividen terakhir dari MedMira tanggal 19/11/2024 sejumlah 0 CAD, Anda harus memiliki saham tersebut di portofolio sebelum tanggal Ex-Tag pada 19/11/2024.

Pembayaran dividen terakhir dilakukan pada 19/11/2024.

Pada tahun 2023, MedMira 0 CAD telah dibayarkan sebagai dividen.

Dividen dari MedMira dibayarkan dalam CAD.